Revance Therapeutics Inc Estimates Total Non-Cash Impairment Charges From Goodwill And Other Assets To Be Between An Estimated $80M-$100M; Anticipates Completion Of Activities, Including Workforce Reduction, Will Be Complete By March 31, 2024
Portfolio Pulse from Benzinga Newsdesk
Revance Therapeutics Inc has estimated total non-cash impairment charges from goodwill and other assets to be between $80M-$100M. The company anticipates completion of activities, including workforce reduction, by March 31, 2024, according to an SEC filing.
September 19, 2023 | 1:15 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Revance Therapeutics is facing significant non-cash impairment charges and workforce reduction, which could negatively impact the company's financial performance and stock price.
The announcement of non-cash impairment charges and workforce reduction indicates financial difficulties for Revance Therapeutics. This could lead to a decrease in investor confidence, potentially driving down the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100